Immunovant will discontinue development of imeroprubart in cutaneous lupus erythematosus after the phase 2b study failed to meet its primary endpoint.
News|Slideshows|February 28, 2025
SLIDESHOW: A Look at 5 Rare Skin Conditions
Listen
0:00 / 0:00
Today, Dermatology Times recognizes Rare Disease Day in an effort to amplify the voices of the over 300 million individuals affected by rare diseases.
Advertisement
References
- Rare Disease Day. What is Rare Disease Day? Accessed February 26, 2025.
https://www.rarediseaseday.org/what-is-rare-disease-day/ - Schmieder SJ, Sathe NC, Rosario-Collazo JA. Darier Disease. In: StatPearls. Treasure Island (FL): StatPearls Publishing; November 30, 2023.
- Khanna D, Bardhan A. Epidermolysis bullosa. In: StatPearls. Treasure Island (FL): StatPearls Publishing; January 11, 2024.
- Konstantinou MP, Krasagakis K. Benign familial pemphigus (Hailey-Hailey Disease). In: StatPearls. Treasure Island (FL): StatPearls Publishing; August 14, 2023.
- Ngan V. Netherton syndrome. DermNet. Published 2005. Accessed February 26, 2025.
https://dermnetnz.org/topics/netherton-syndrome - Ingold CJ, Sathe NC, Khan MAB. Pemphigus vulgaris. In: StatPearls. Treasure Island (FL): StatPearls Publishing; March 1, 2024.
Advertisement
Related to this article
The designation marks the first FDA Fast Track status granted to a therapy for peeling skin syndrome, which currently has no approved treatment.
LEO Pharma has closed its acquisition of dersimelagon from Tanabe Pharma after the FDA accepted the drug's NDA for filing and granted Priority Review, with a PDUFA date expected by the end of February 2027.
Sol-Gel Technologies has completed patient follow-up in its pivotal phase 3 trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, with top-line results expected in late November 2026.
The FDA has set a PDUFA target action date of June 29, 2027, based on APEX trial data showing a 65% overall response rate in advanced systemic mastocytosis.
Victoria Werth, MD, professor of dermatology and rheumatology at the University of Pennsylvania, recently discussed brepocitinib's FDA approval for dermatomyositis and what the VALOR trial data mean for patients and clinicians.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
Advertisement
Advertisement
Trending on Dermatology Times
1
From Mechanism to Management: Navigating Male Pattern Hair Loss and New Topical Therapies
2
FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata
3
Tremfya Meets Primary, Major Secondary Endpoints in Phase 4 STAR Study of Axial PsA
4
Dermatology Times Spot Test: September 27, 2026
5